Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan.

Journal of endocrinological investigation - 1 Dec 2025

Tuccinardi Dario, Masi Davide, Watanabe Mikiko, Zanghi Buffi Valeria, De Domenico Francesco, Berti Sabrina, Cipriani Valentina, Manco Melania, Manfrini Silvia, Pagotto Uberto

Abstract excerpt

OBJECTIVE: Obesity is a biologically complex and heterogeneous disease that requires individualized, phenotype- and complication-oriented therapeutic strategies. The introduction of advanced pharmacotherapies, including GLP-1 receptor agonists (GLP-1 RA), dual Glucose-dependent Insulinotropic Polypeptide/Glucagon-like Peptide-1 (GIP/GLP-1) agonists, and emerging triple agonists, has facilitated a shift from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to GIP gene
Share to Longevity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Obesity

Share to Phenotype

Share to Precision Medicine

Source

Open in PubMed Open full text

Identifiers

PMID: 41212412
DOI: 10.1007/s40618-025-02700-7
PMCID: PMC12640352

Genes

GIP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan.PMID 41212412Read ↗

Phenotype-Directed Precision Therapeutics: A Framework for Multi-Agonist Therapy in Obesity, MASH and Cardio-Renal-Metabolic DisordersSemantic proximity Read ↗

Phenotype-Directed Precision Therapeutics: A Framework for Multi-Agonist Therapy in Obesity, MASH and Cardio-Renal-Metabolic DisordersSemantic proximity Read ↗

From one-size-fits-all to phenotype-based pharmacotherapy: How far are we in obesity management?Semantic proximity Read ↗

Precision nutrition for targeting pathophysiology of cardiometabolic phenotypes.Semantic proximity Read ↗

Greater lean-body-mass decline with tirzepatide than semaglutide in routine care, revealed by body-composition digital phenotypingSemantic proximity Read ↗

Greater lean-body-mass decline with tirzepatide than semaglutide in routine care, revealed by body-composition digital phenotypingSemantic proximity Read ↗

Treatment of obesity: should we target the individual or society?Semantic proximity Read ↗

Incident Frailty and Mortality Risk with Significant Tirzepatide-Associated Weight Loss in Medicare-Age PatientsSemantic proximity Read ↗

The heterogeneity of metabolic syndrome presentation and challenges this causes in its pharmacological management: a narrative review focusing on principal risk modifiers.Semantic proximity Read ↗

Cardiovascular Outcomes of Tirzepatide vs Semaglutide in Obesity Without Type 2 Diabetes: A Matched Cohort StudySemantic proximity Read ↗

Tirzepatide Synergizes with Leptin on Weight Loss and Restoring Metabolic Homeostasis in Diet-induced Obesity ModelSemantic proximity Read ↗

Emerging Trends in Endoscopic Bariatric Therapies: Personalization Through Genomics and Synergistic PharmacotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.